Today: 21 May 2026
Nu Holdings stock jumps 5% to near $18 — what’s driving NU and what investors watch next
6 January 2026
1 min read

Nu Holdings stock jumps 5% to near $18 — what’s driving NU and what investors watch next

New York, Jan 5, 2026, 21:21 EST — Market closed

Nu Holdings Ltd (NU.N), the parent of Brazilian digital lender Nubank, gained 5.4% on Monday to about $17.94 after trading between $17.02 and $18.14. Volume topped 74 million shares.

The move matters now because NU is pushing into the $18 handle just as investors start to price in the first wave of quarterly results and recalibrate risk after a strong 2025 run for equities.

It also leaves the stock closer to where many analysts peg fair value, raising the bar for the next catalyst to keep the rally intact.

Financial stocks set the tone on Wall Street, with the sector leading broader gains. “The mood has been favoring financial stocks in recent days,” said Steve Sosnick, chief market analyst at Interactive Brokers. Reuters

Brazil-linked lenders rose alongside Nu, with Itaú Unibanco (ITUB.N) up about 2% and Banco Bradesco (BBD.N) up roughly 4.8% in U.S. trading.

In its most recent results, Nu reported third-quarter net income of $783 million, up 39% on a currency-neutral basis — stripping out exchange-rate swings — and posted a record 31% return on equity, a measure of profit per dollar of shareholder capital, Reuters reported in November.

Regulation has stayed on the radar. Nubank said in December it intends to obtain a banking license in Brazil in 2026 by adding a banking institution to its conglomerate, while keeping its brand and visual identity unchanged.

Analysts tracked by MarketBeat have an average 12-month price target of $18.04 for NU, with estimates ranging from $16 to $21.

MarketBeat lists Nu’s next earnings date as an estimate for Feb. 19, after market close, and notes the company has not confirmed the timing.

But the run leaves Nu exposed if risk appetite fades or if credit losses rise in its consumer loan book, especially in a higher-rate or weaker-growth environment across its core markets.

For Tuesday’s session, traders will watch whether NU can hold above the $18 area, with support around $17. Macro focus turns to the U.S. Employment Situation report for December, due Friday at 8:30 a.m. ET.

Stock Market Today

  • Q1 Earnings Analysis: Pegasystems Lags, Appian Leads Automation Software Stocks
    May 20, 2026, 8:03 PM EDT. As Q1 earnings wrap up in the automation software sector, Pegasystems (NASDAQ:PEGA) posted a disappointing 9.6% revenue decline to $430 million, missing analyst estimates by 7.3%. Its stock dropped 11.8% post-report. Conversely, Appian (NASDAQ:APPN) showed robust growth with a 21.5% revenue increase to $202.2 million, beating expectations by 5.6%, yet its shares fell 9.2%. The sector overall saw revenues exceed consensus by 0.8%, but stocks fell 6.5% on average after earnings. Pegasystems' approach centers on AI-driven workflow automation, while Appian offers a low-code platform for complex processes. These contrasting performances highlight varied market reactions despite solid fundamental advances in automation software driven by AI and machine learning integration.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV
Previous Story

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

Why Commonwealth Bank (ASX:CBA) shares fell 3% as Australia’s CPI test nears
Next Story

Why Commonwealth Bank (ASX:CBA) shares fell 3% as Australia’s CPI test nears

Go toTop